Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

News

Do PCSK9 inhibitors increase new-onset diabetes? Another meta-analysis

Do PCSK9 inhibitors increase new-onset diabetes? Another meta-analysis

A new meta-analysis involving more than 26,000 patients reports no increase in new-onset diabetes and no impact on glucose metabolism with PCSK9 inhibitor treatment. The authors performed a comprehensive medical literature to identify 18 randomized controlled studies with 26,123 patients without diabetes at study baseline….

read more »
ODYSSEY OUTCOMES to report at ACC.2018

ODYSSEY OUTCOMES to report at ACC.2018

The second completed cardiovascular outcomes study with a PCSK9 inhibitor will be up first at the first latebreaker session at the American College of Cardiology Scientific Sessions this March. ODYSSEY OUTCOMES with alirocumab follows reporting of FOURIER with evolocumab and the terminated SPIRE studies with…

read more »
Highest risk-highest benefit from PCSK9 inhibition

Highest risk-highest benefit from PCSK9 inhibition

Using a pragmatic approach, experts have recommended a ‘highest risk–highest benefit’ strategy for clinicians considering PCSK9 inhibitor treatment for their patients. This takes into account the clinical need, outcome benefit and cost of the PCSK9 inhibitors. Briefly, ‘highest risk’ refers to patients with the highest…

read more »
Why we need PCSK9 inhibitors: goal attainment too low with statin plus ezetimibe

Why we need PCSK9 inhibitors: goal attainment too low with statin plus ezetimibe

Guidelines recommend adding ezetimibe if patients fail to attain LDL cholesterol goal on statin alone. However, this study concludes that in a real-world setting, addition of ezetimibe had only a small impact on the number of high risk patients achieving an LDL cholesterol <1.8 mmol/L…

read more »
Identifying and Treating Severe Familial Hypercholesterolaemia: Course Slides online

Identifying and Treating Severe Familial Hypercholesterolaemia: Course Slides online

The International Atherosclerosis Society-mentored course on severe familial hypercholesterolaemia (FH, inherited high cholesterol), held in Dubai, UAE on October 14-15, 2017, has now published slides and abstracts online. Slides are available at: http://www.athero.org/SevereFHCourse20171014/index.asp and Scientific Program & Abstracts at http://www.athero.org/SevereFHCourse20171014/FinalProgramAbstarctsCVsSocieties.pdf

read more »
Alirocumab shows benefit in SAMS with myotonic dystrophy

Alirocumab shows benefit in SAMS with myotonic dystrophy

There are currently few options for patients with statin intolerance and myotonic dystrophy. In this case report, a 74-year-old male with hypercholesterolaemia (serum LDL cholesterol 210 mg/dL), hypogonadism, insulin-controlled type 2 diabetes mellitus, and minimally elevated serum creatine kinase levels (184 U/L, ref. range 38-174),…

read more »
PCSK9 inhibitors: effects on glycaemia and HbA1c

PCSK9 inhibitors: effects on glycaemia and HbA1c

Treatment with a PCSK9 inhibitor for a mean of 1.5 years led to a small albeit significant increase in plasma glucose and HbA1c, according to the results of this meta-analysis of more than 68,000 patients treated in phase 2/3 trials. With this short duration of…

read more »
ODYSSEY-KT: Alirocumab shows benefit in trial in S. Korea and Taiwan

ODYSSEY-KT: Alirocumab shows benefit in trial in S. Korea and Taiwan

This trial showed the benefit of PCSK9 inhibition in high risk patients from these countries, evidence for which had been lacking to date. The study enrolled 199 individuals from South Korea and Taiwan (mean age 61 years, 82% male) with hypercholesterolaemia and coronary heart disease…

read more »
FDA approves evolocumab to prevent heart attack, stroke, and coronary revascularization

FDA approves evolocumab to prevent heart attack, stroke, and coronary revascularization

The U.S. Food and Drug Administration (FDA) has approved evolocumab as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease. The approval was supported by data from the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition…

read more »
More poster news: Patient-reported barriers to use of PCSK9 inhibitors

More poster news: Patient-reported barriers to use of PCSK9 inhibitors

Results from this web-based US survey show that cost was the main reason given by patients for low initial and ongoing use of PCSK9 inhibitors. This survey was completed by 769 patients who signed up for a pharmaceutical company-sponsored patient support program after prescription for…

read more »
More poster news: Adherence to PCSK9 inhibitor therapy

More poster news: Adherence to PCSK9 inhibitor therapy

In the ODYSSEY Open-Label Extension Study, adherence to continuation of alirocumab treatment was not an issue. The ODYSSEY Open-Label Extension Study included patients with heterozygous familial hypercholesterolemia (FH, inherited high cholesterol) after completion of 4 Phase 3 placebo-controlled studies (FH I, FH II, LONG TERM,…

read more »
More real-world experience with PCSK9 inhibitors

More real-world experience with PCSK9 inhibitors

In this report from Charité Berlin, PCSK9 inhibitor therapy was effective in 499 patients with high and very high cardiovascular risk and substantial LDL cholesterol burden. Patients were either unable to attain guideline defined LDL cholesterol goal with maximally tolerated lipid lowering therapy or were…

read more »
GLAGOV diabetes analysis: atheroma regression with evolocumab similar to nondiabetics

GLAGOV diabetes analysis: atheroma regression with evolocumab similar to nondiabetics

Treatment with evolocumab resulted in comparable regression of coronary atherosclerosis in statin-treated patients with and without diabetes, reinforcing the need for intensive lipid lowering in diabetes patients. GLAGOV (GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound) compared the effects…

read more »
SPIRE FH Analysis: PCSK9 inhibition reduces cardiovascular events in FH patients

SPIRE FH Analysis: PCSK9 inhibition reduces cardiovascular events in FH patients

Statin-treated patients with familial hypercholesterolaemia (FH, inherited high cholesterol) derive a similar reduction in cardiovascular events with the PCSK9 inhibitor bococizumab as patients without FH, according to this analysis of data from six SPIRE studies. Outcomes trials in FH patients in the modern era of…

read more »
AHA Scientific Sessions 2017: More insights from FOURIER into very high-risk patients: PAD and high-risk MI

AHA Scientific Sessions 2017: More insights from FOURIER into very high-risk patients: PAD and high-risk MI

New analyses from FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) reinforce the very high risk of cardiovascular events in patients with  peripheral arterial disease (PAD), recurrent myocardial infarction (MI) and multivessel disease. In patients with PAD, evolocumab on top…

read more »
Ten Countries Study: Familial hypercholesterolaemia care lags behind in the Asia-Pacific region

Ten Countries Study: Familial hypercholesterolaemia care lags behind in the Asia-Pacific region

Familial hypercholesterolaemia (FH, inherited high cholesterol) is the most common and serious form of inherited hyperlipidaemia (1). Yet, despite its clinical importance, there is still a major shortfall in FH care. Much of the information relates to Europe and North America; the Ten Countries aimed…

read more »
More real-world data with PCSK9 inhibitors

More real-world data with PCSK9 inhibitors

In the light of cardiovascular outcomes data from FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) (1), the Joint Task Force of the European Society of Cardiology and European Atherosclerosis Society recently updated practical guidance for the use of PCSK9…

read more »
Cholesterol variability is a predictor of adverse outcome in the general population

Cholesterol variability is a predictor of adverse outcome in the general population

Data from a large Korean cohort highlights visit-to-visit variability in cholesterol levels as an important cardiovascular risk factor in the general population.  This adds to previous evidence that variability in cholesterol levels is an independent predictor of major adverse cardiovascular events in patients with coronary…

read more »
New meta-analysis reaffirms benefit of more intensive LDL lowering on cardiovascular outcome

New meta-analysis reaffirms benefit of more intensive LDL lowering on cardiovascular outcome

Irrespective of the type of therapy, more intensive lowering of LDL cholesterol was associated with 19% reduction in major vascular endpoints compared with less intensive treatment. This meta-analysis identified 19 trials (15 with statins, 3 with PCSK9 inhibitors, and one with ezetimibe) in 152,507 patients…

read more »
Why the 2017 ESC/EAS practical guidance on PCSK9 inhibition is needed

Why the 2017 ESC/EAS practical guidance on PCSK9 inhibition is needed

In the largest US analysis to date, higher LDL cholesterol levels were not associated with higher payer approval rates for PCSK9 inhibitor therapy. These data reaffirm the need for practical guidance, such as that published by a Joint Task Force from the European Society of…

read more »